NCT02540161View on ClinicalTrials.gov

Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 1, 2016

Primary Completion Date

July 10, 2019

Study Completion Date

April 27, 2020

Conditions
Malignant Glioma
Interventions
DRUG

Sym004 - 18 mg/kg

Sym004 was dosed at 18 mg/kg intravenously every two weeks.

DRUG

Sym004 - 24 mg/kg

Beginning in August 2017, the dose was increased to 24 mg/kg intravenously every two weeks.

Trial Locations (1)

27710

The Preston Robert Tisch Brain Tumor Center, Durham

All Listed Sponsors
collaborator

Symphogen A/S

INDUSTRY

lead

Annick Desjardins

OTHER

NCT02540161 - Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter